Summary
To explore the pharmacokinetics and tolerability of AZD2171, an inhibitor of vascular endothelial growth factor receptors 1 and 2, in patients with hormone refractory prostate cancer. Twenty-six patients received oral daily dosing of AZD2171 at 1, 2.5, 5, 10, 20, 30 mg. The maximum tolerated dose (MTD) was defined as the dose below that at which ≥33% of patients experienced a dose-limiting toxicity (DLT) within 21 days of initiating therapy. Pharmacokinetic analysis was performed. DLTs occurred at the 30 mg dose and included grade 3 events in three patients: fatigue (n = 3) and muscle weakness (n = 2). The pharmacokinetic profile revealed an effective half-life of approximately 27 h. At steady state, the unbound drug concentration was 4.4 times above the concentration required to inhibit endothelial cell proliferation in vitro. Four patients experienced PSA reductions within 30 days following drug discontinuation (one on 2.5 mg, two on 20 mg and 1 on 30 mg). In two patients treated with 20 mg, post therapy PSA declines persisted for >17 months, despite a PSA increase on therapy. Resolution of adenopathy occurred in one patient persisting for >17 months. Plasma concentrations were maximum 2–8 h post dosing with an overall median value of 2 h. The dose of 20 mg daily was declared as the MTD. One objective response and several PSA declines following the discontinuation of therapy for toxicity suggest that evidence of clinical efficacy may be delayed. While further study is indicated, careful attention must be paid to the novel toxicities of this agent with prolonged dosing.
Similar content being viewed by others
References
Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987–989
Weidner N, Carrol PR, Flax J, et al (1993) Tumor angiogensis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401–408
Bok RA, Halabi S, Fei DT, et al (2001) Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 61:2533–2536
George DJ, Halabi S, Shepard TF, et al (2001) Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7:1932–1936
Huss WJ, Hanrahan CF, Barrios RJ, et al (2001) Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 61:2736–2743
John V, Mashru S, Lichtman S (2003) Pharmacological factors influencing anticancer drug selection in the elderly. Drugs Aging 20:737–759
Wedge SR, Kendrew J, Hennequin LF, et al (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389–4400
Bubley GJ, Carducci M, Dahut W, et al (1999) Eligibility and response guidelines for phase II clinical trials in androgen-indpendent prostate cancer: recommendations from the PSA Working Group. J Clin Oncol 17:3461–3467
Sopher BL, Thomas PS, Jr., LaFevre-Bernt MA, et al (2004) Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration. Neuron 41:687–699
Dahut WL, Scripture CD, Posadas EM, et al (2006) Bony metastatic disease responses to sorafenib (BAY 43-9006) independent of PSA in patients with metastatic androgen independent prostate cancer. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. pp 450
Kelly WK, Scher HI (1993) Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 149:607–609
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ryan, C.J., Stadler, W.M., Roth, B. et al. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs 25, 445–451 (2007). https://doi.org/10.1007/s10637-007-9050-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-007-9050-y